Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 15,948 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 2 Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate D-1553 in Subjects With Solid Tumors

NCT04585035
View directory record Official record
Conditions
Solid Tumor, Adult, NSCLC, CRC
Interventions
D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Fresno, California • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 29, 2026, 8:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225
View directory record Official record
Conditions
Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 1Phase 2 Interventional

Improving Fecal Occult Blood Test Completion Rates Among Veterans

NCT01516489
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Stage 1, Stage 2
Behavioral
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
Male only
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 3 Interventional

Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease

NCT00393250
View directory record Official record
Conditions
Sickle Cell Disease, Pain Management
Interventions
Hypnosis, Control
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 29, 2026, 8:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

NCT06364774
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ALS20
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 29, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional Results available

Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

NCT03574818
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
Necitumumab-Gemcitabine-Cisplatin, Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
Drug · Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches

NCT06569290
View directory record Official record
Conditions
Diabetes, Pharmacist-Patient Relations, Medication Adherence
Interventions
Primer postcard, Control recruitment letter, Behavioral theory-informed recruitment letter (prospect theory), 2 phone calls, 4 phone calls
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Not yet recruiting Not applicable Interventional

Prediction and Prevention of Postoperative Mortality and Morbidity

NCT06042413
View directory record Official record
Conditions
Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions
Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care
Other · Behavioral · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Not listed Phase 1Phase 2 Interventional

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

NCT00738413
View directory record Official record
Conditions
Thalassemia
Interventions
Deferoxamine, Deferasirox
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 2 Interventional Results available

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

NCT02253420
View directory record Official record
Conditions
Medical Oncology
Interventions
Copanlisib (BAY80-6946), Itraconazole, Rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

NCT01514123
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
VGX-100, Bevacizumab
Drug
Lead sponsor
Circadian Technologies Ltd.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

NCT00677859
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
MultiStem®
Biological
Lead sponsor
Healios K.K.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 29, 2026, 8:51 PM EDT
Active, not recruiting Not applicable Interventional

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

NCT04917796
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful, Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Electroacupuncture, Sham Acupuncture
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Withdrawn Phase 1Phase 2 Interventional

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

NCT01624493
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Carboplatin, Gemcitabine, BNC105P
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 29, 2026, 8:51 PM EDT
Recruiting No phase listed Observational

ViewFlex X ICE First-in-Human Study

NCT06772493
View directory record Official record
Conditions
Cardiac Arrhythmias
Interventions
ViewFlex X ICE System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Jonesboro, Arkansas • La Jolla, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Terminated Phase 1Phase 2 Interventional

IMM60 and Pembrolizumab in Melanoma and NSCLC

NCT05709821
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Melanoma
Interventions
IMM60, Pembrolizumab
Drug
Lead sponsor
iOx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 29, 2026, 8:51 PM EDT
Recruiting Phase 1 Interventional

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

NCT06631521
View directory record Official record
Conditions
Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
Interventions
Darolutamide, Relugolix, Radical Prostatectomy
Drug · Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Informing American Muslims About Living Donation

NCT04443114
View directory record Official record
Conditions
Living Organ Donation
Interventions
Organ Donation Workshop, End of Life Care Workshop
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 29, 2026, 8:51 PM EDT
Not listed Not applicable Interventional

The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study

NCT01323114
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Laparoscopic duodenal exclusion, Conventional Medical Treatment
Procedure · Other
Lead sponsor
McKenzie Health System
Other
Eligibility
20 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Sandusky, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 29, 2026, 8:51 PM EDT
Not yet recruiting Not applicable Interventional

Trial of Total Lung Protective Ventilation in Adult VV-ECMO Patients With Severe ARDS

NCT07790133
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome), VV ECMO
Interventions
Mechanical Power Targeted Ventilation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 8:51 PM EDT
Terminated Phase 2 Interventional Results available

Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

NCT03439033
View directory record Official record
Conditions
Prostate Cancer
Interventions
PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, PET/CT with Gallium-68 labeled PSMA-HBED-CC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older · Male only
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 29, 2026, 8:51 PM EDT